It is easy to become intimidated, but traders just need to deleverage.
Even if it doesn't find a buyer, Groupon appears to offer a decent risk-reward.
This list of high-yield-dividend-paying funds shows how payouts can make the difference between investing profitability or taking a loss.
The central bank is in a new phase of monetary policy, but the market doesn't quite realize it yet.
First Trust NYSE Arca Biotechnology Index Fund and iShares Nasdaq Biotechnology ETF look like two ways to catch the rally in Biogen.
I like these to be worth double by Friday.
It's hard to predict movements in stocks in China, a job made even harder amid saber-rattling over tariffs and trade.
These three funds seem well-positioned to take advantage of a growing overseas middle class.
The positive chatter is gone -- and there are plenty of excuses.
Look for the ETF to be back to the lows by the end of next month.